Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
42 hedge funds and large institutions have $95.7M invested in Impel Pharmaceuticals Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 8 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.31% less ownership
Funds ownership: 66.28% → 64.97% (-1.3%)
7% less funds holding
Funds holding: 45 → 42 (-3)
27% less capital invested
Capital invested by funds: $132M → $95.7M (-$36.1M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$839K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$303K |
| 3 |
Renaissance Technologies
New York
|
+$251K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$249K |
| 5 |
State Street
Boston,
Massachusetts
|
+$84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.8M |
| 2 |
Two Sigma Investments
New York
|
-$1.23M |
| 3 |
Two Sigma Advisers
New York
|
-$504K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$153K |
| 5 |
Millennium Management
New York
|
-$128K |
IMPL Hedge Fund Activity: Q1 2022 in Review
42 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q1 2022, worth a combined $95.7M — down 27% from $132M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of IMPL and 5 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 13 added.
The largest buyer was DCF Advisers, adding an estimated $839K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.8M sold.
- 42 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q1 2022, down from 45 in Q4 2021.
- Funds reported $95.7M of Impel Pharmaceuticals Inc. Common Stock stock for Q1 2022, down 27% quarter-over-quarter.
- 5 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q1 2022 and 8 closed out, a net change of -3 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q1 2022 was DCF Advisers, an estimated $839K added.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q1 2022 was Point72 Asset Management, an estimated $1.8M sold.
Based on aggregated 13F filings for Q1 2022.